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The growth hormone–insulin-like growth factor–insulin-like growth factor binding
protein (GH–IGF–IGFBP) axis plays a critical role in the maintenance of normal renal
function and the pathogenesis and progression of chronic kidney disease (CKD). Serum
IGF-I and IGFBPs are altered with different stages of CKD, the speed of onset, the amount
of proteinuria, and the potential of remission. Recent studies demonstrate that growth
failure in children with CKD is due to a relative GH insensitivity and functional IGF
deﬁciency. The functional IGF deﬁciency in CKD results from either IGF resistance due to
increased circulating levels of IGFBPs or IGF deﬁciency due to increased urinary excretion
of serum IGF–IGFBP complexes. In addition, not only GH and IGFs in circulation, but
locally produced IGFs, the high-afﬁnity IGFBPs, and low-afﬁnity insulin-like growth factor
binding protein-related proteins (IGFBP-rPs) may also affect the kidney. With respect to
diabetic kidney disease, there is growing evidence suggesting that GH, IGF-I, and IGFBPs
are involved in the pathogenesis of diabetic nephropathy (DN). Thus, prevention of GH
action by blockade either at the receptor level or along its signal transduction pathway
offers the potential for effective therapeutic opportunities. Similarly, interrupting IGF-I
and IGFBP actions also may offer a way to inhibit the development or progression of DN.
Furthermore, it is well accepted that the systemic inﬂammatory response is a key player
for progression of CKD, and how to prevent and treat this response is currently of great
interest. Recent studies demonstrate existence of IGF-independent actions of high-afﬁnity
and low-afﬁnity-IGFBPs, in particular, antiinﬂammatory action of IGFBP-3 and proﬁbrotic
action of IGFBP-rP2/CTGF. These ﬁndings reinforce the concept in support of the clinical
signiﬁcance of the IGF-independent action of IGFBPs in the assessment of pathophysiol-
ogy of kidney disease and its therapeutic potential for CKD. Further understanding of GH–
IGF–IGFBP etiopathophysiology in CKD may lead to the development of therapeutic
strategies for this devastating disease. It would hold promise to use of GH, somatostatin
analogs, IGFs, IGF agonists, GHR and insulin-like growth factor-I receptor (IGF-IR)
antagonists, IGFBP displacer, and IGFBP antagonists as well as a combination treatment
as therapeutic agents for CKD.
& 2012. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).rean Society of Nephrology. Published by Elsevier. This is an open access article under the CC BY-NC-
ses/by-nc-nd/4.0/).
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In 2002, the U.S. National Kidney Foundation’s Kidney
Disease Outcomes Quality Initiative (K/DOQI) clinical
practice guidelines provided for the ﬁrst time a working
deﬁnition of chronic kidney disease (CKD), irrespective of
the cause of kidney disease, based on the presence of
kidney damage and/or reduced estimated glomerular
ﬁltration rate for more than 3 months. CKD is largely
caused by diabetes, hypertension, glomerulonephritis,
obesity, and metabolic syndrome [1–7]. Moreover, CKD
is recognized as a major risk factor for end-stage renal
disease (ESRD), cardiovascular disease, and cardiovascular
disease-related premature death [8,9]. CDK is fast becom-
ing a worldwide epidemic and recognized as a major
public health problems, with 26 million American adults
suffering from CKD and millions of others at increased risk
[10]. CKD results in complex metabolic and hormonal
disturbances, particularly in the growth hormone–
insulin-like growth factor–insulin-like growth factor bind-
ing protein (GH–IGF–IGFBP) axis. Perturbations in this
somatotropic hormone axis are responsible for many
important complications seen in CKD, such as growth
retardation and catabolism, as well as disease progression.
This review will focus on recent discoveries and insights
into the IGF system and its therapeutic potential in CKD.The IGF system
GH–IGF axis
GH exerts its somatotropic effects partially by stimulat-
ing the production of IGF-I in the liver through activation
of hepatic GH receptor. IGF-I is transported to the main
target organs via the circulation to act as an endocrine
factor [11]. In addition, circulating IGF-I acts as a feedback
on the somatotropic axis and suppresses the release of GH
from the pituitary gland [11].
The IGF–IGFBP–IGF-rP superfamily
IGF-I, IGF-II, their cognate receptors (insulin-like
growth factor-I receptor [IGF-IR] and insulin-like growth
factor-II receptor [IGF-IIR]), high-afﬁnity binding proteinsIGFBPs  1-5
IGFBP-6
IGFBP-rP1 (MAC25)
NH2 GCGCCxxC
IGFBP-rP2 (CTGF) 
IGFBP-rP4 (CYR61) 
IGFBP-rP3 (NOV) 
Figure 1. Schematic primary structures of high-afﬁnity insulin-like grow
like growth factor binding protein-related proteins (IGFBP-rPs). Numbers
locations of the cysteines are indicated as vertical lines. The conserved N- a
motif GCGCCxxC is as indicated.(IGFBP-1 to IGFBP-6), low afﬁnity IGFBP-related proteins
(IGFBP-rP1 to IGFBP-rP7), and IGFBP proteases comprise a
complex system that plays a signiﬁcant role not only in
somatic growth and body composition but also in diseases
such as cancer, diabetes, and malnutrition by serving as
endocrine, autocrine, and paracrine stimulators of mito-
genesis, differentiation, survival, and cellular transforma-
tion [12].
IGF-I and -II peptides: These hormones share approxi-
mately 50% homology to insulin. They are ubiquitously
expressed, highly homologous small hormone peptides of
approximately 7 kDa molecular mass with multiple endo-
crine and paracrine/autocrine activities [12]. Most circu-
lating IGF-I is produced by the liver and is responsible for
growth and development.
IGF-I and -II receptors: IGFs interact with speciﬁc cell
surface receptors, designated as IGF-I and IGF-II receptors.
The IGF-I receptor is a transmembrane heterotetramer
consisting of two a and two b subunits. There is approxi-
mately 60% sequence homology between the IGF-I recep-
tor and the insulin receptor [13]. The IGF-I receptor, like
the insulin receptor (IR), possesses intrinsic tyrosine
kinase activity. IGF-II also binds to the IGF-I receptor but
with twofold lower afﬁnity than IGF-I [13]. The IGF-II
receptor, which is identical to the cation-independent
mannose-6-phosphate receptor, binds IGF-II with 500-fold
increased afﬁnity over IGF-I [14]. Most of the biologic
actions of IGF-II are thought to be mediated via the IGF-I
receptor [14]. The IGF-II receptor is known to function
primarily as a scavenger receptor, regulating the inter-
nalization and degradation of extracellular IGF-II, thus
regulating the circulating IGF-II levels.
High-afﬁnity IGFBPs: A total of six high-afﬁnity binding
proteins have been identiﬁed, IGFBP-1 through IGFBP-6
[15–18] (Fig. 1). Hepatic IGF-I circulates almost entirely
bound to IGFBPs. IGFBP-3, a major IGFBP species in
circulation, binds 75–90% of circulating IGF-I in a large
ternary complex consisting of IGFBP-3, acid-labile subunit
(ALS), and IGF. ALS and IGFBP-3 are produced in the liver
as a direct or indirect effect of GH. The ALS stabilizes the
IGF–IGFBP-3 complex, reduces the passage of IGF-I to the
extravascular compartment, and extends its half-life [19].
It is evident that certain high-afﬁnity IGFBPs have intrinsic
hormone activity (IGF-independent actions) in addition toCOOH
16
12
17
17
17
18
th factor binding protein-1 (IGFBP-1) to -6 and low-afﬁnity insulin-
of conserved cysteines are indicated on the right of each structure, and
nd C-terminal domains are shown as dark, stippled bars. The consensus
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thereby reducing IGF biologic activity (IGF-dependent
actions) [20].
Low-afﬁnity IGFBP-rPs: Several low-afﬁnity IGFBP-rPs
have been identiﬁed [12] (Fig. 1). The IGFBP-rPs are
cysteine rich, and consist of four modules; an IGF binding
domain, a von Willebrand factor type C repeat (involved in
oligomerization), a thrombospondin type 1 repeat
(involved in extracellular matrix [ECM] binding), and a
C-terminal module, which may be involved in receptor
binding. The IGFBP-rPs bind to IGFs with more than
100-fold lower afﬁnity compared with the IGFBPs. The
100-fold lower afﬁnity of IGFBP-rPs for IGFs is believed to
result from loss of the C-terminal domain of IGFBPs, and
both C- and N-termini are thought to be required for high-
afﬁnity binding [12]. Further, the IGFBP-rPs has actions
that are predominantly independent of IGFs. In this
review, we only address IGFBP-rP2 with respect to its
physiologic signiﬁcance and pathophysiology in intersti-
tial ﬁbrosis in the kidney.
IGFBP proteases: These proteases constitute another
means for the regulation of IGF bioactivity and IGFBP
actions. The IGF/IGFBP complex can be dissociated by
proteases that cleave IGFBPs. In addition, certain free
IGFBPs can also be proteolyzed by speciﬁc proteases,
resulting in loss of high afﬁnity for IGFs. To date, several
proteases for IGFBPs have been described in biologic ﬂuids
and a variety of cell culture systems. These include serine
proteases, prostate-speciﬁc antigen (PSA), cathepsins, and
matrix metalloproteinases [21].
IGF/IGF-IR-dependent and IGF/IGF-IR-independent actions of
IGFBPs
IGF-dependent actions of IGFBPs
IGFBPs are known to modulate the actions of IGFs in
circulation as well as the immediate extracellular envir-
onment [16,17]. Many IGFBPs inhibit IGF actions by
binding them and preventing binding of IGFs to the IGF
receptors [22,23]. There are in vivo studies showing that
IGFBPs reduce the level of free IGF, thereby inhibiting
growth [24–26]. The use of an IGF analog des-(1–3)-IGF-I
conﬁrmed the sequestration mechanism in in vitro and
in vivo studies. The IGF analog binds to IGF-IR and
stimulates DNA synthesis, but does not bind to IGFBPs
[27]. It has also been reported that a number of IGFBPs
(e.g., IGFBPs-1, -3 and -5) stimulate IGF actions in a variety
of cell types. A single IGFBP can enhance or inhibit IGF
actions, depending on a number of variables, such as cell
type, IGFBP concentration, and posttranslational modiﬁca-
tions [17,18]. These include proteolysis of IGFBPs, phos-
phorylation of IGFBPs, and binding of IGFBPs to ECM
proteins. IGFBP proteases are capable of cleaving IGFBPs
into forms with signiﬁcantly reduced or no afﬁnity for
IGFs. Some IGFBPs (e.g., IGFBP-1 and -5) on phosphoryla-
tion exhibit increased afﬁnity to IGF-I, whereas some
remain unaffected by phosphorylation [28,29]. IGFBPs,
especially IGFBP-3 and IGFBP-5, have been reported to
bind to the cell surface or ECM and show less afﬁnity
[16–18].IGF-independent functions of IGFBPs
IGFBPs have a multitude of functions from prolonging
the half-life of IGFs to playing the role of growth factors
independent of IGF/IGF-R. IGF/IGF-IR independent effects
of IGFBPs occur either by IGFBP binding to its binding
partners on the cell surface, in cytoplasm or nucleus in
certain cell types. IGF-independent actions of IGFBPs
include effects on cell migration, cell growth, and apopto-
sis. IGFBP-1 has been reported to increase cell migration
through binding to the ﬁbronectin receptor [30]. Recent
study also demonstrates an IGF-independent effect of
IGFBP-5 in osteoblasts from IGF-I knockout mice [31].
IGFBP-3 has important IGF-independent effects in vitro
and in vivo [32]. IGFBP-3 is one of the genes transcription-
ally activated by the tumor suppressor gene p53, whose
function is to induce cell cycle arrest or apoptosis and thus
prevent the propagation of damaged cells [33,34]. Several
lines of evidence reveal that IGFBP-3 exerts proapoptotic
and antiproliferative IGF/IGF-IR independent actions
through IGFBP-3 receptor, IGFBP-3 interacting proteins,
and nuclear association. The concept of IGF-independent
action of IGFBP-3 was ﬁrst demonstrated in breast cancer
cells due to cell surface binding between IGFBP-3 and cell
surface proteins typical of receptor ligand interactions
[35]. A recent article reported the identiﬁcation of a novel
death receptor (IGFBP-3R) that speciﬁcally binds IGFBP-3
and mediates a variety of biologic functions of IGFBP-3
in normal and malignant cells [36–39]. Some of the
additional binding partners of IGFBP-3 are humanin, RNA
polymerase II binding subunit 3 (Rpb3), and GalNAc-T14.
Humanin is a peptide that inhibits neuronal cell death
induced by mutant genes in Alzheimer disease [40]. Rpb3
aids the recruitment of the polymerase complex to speciﬁc
transcription factors leading to the role of IGFBP-3 in the
modulation of gene transcription [41]. IGFBP-3 has a
nuclear localization sequence and studies show that it
binds to nuclear retinoid X receptor (RXR), which is
involved in physiologic function of thyroid hormone and
steroid hormones, embryonic development, apoptosis, and
homeostasis [42–44]. RXR heterodimerizes with Nur77, a
nuclear receptor transcription factor, thereby enhancing
its DNA binding ability and regulating apoptosis in various
cancers [45,46]. In the presence of IGFBP-3, Nur77 trans-
locates to the nucleus and initiates apoptosis [47]. Many
in vitro, in vivo, and epidemiologic studies suggest that
IGFBP-3 may have a protective effect in cancer patients
[48]. This is also emphasized by the fact that higher IGF-I
and lower IGFBP-3 levels are associated with an increased
risk in cancers such as prostate, colorectal, and breast. In
addition, signiﬁcant circulating levels of IGFBP-3 in pros-
tate cancer correlate with slower rate of tumor progres-
sion and better therapeutic response [32,49].
Apart from evidence supporting antitumor effect of
IGFBP-3 in a variety of cancers, evidence exists to suggest
that IGFBP-3 can also act as an antiinﬂammatory factor,
thereby inhibiting physiologic manifestations of asthma
such as airway inﬂammation and hyperresponsiveness
[38]. This involves activation of IGF-independent IGFBP-3
signaling and cross-talk with nuclear factor-kappa B
signaling.
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Figure 2. Insulin-like growth factor (IGF) system gene expression in the human kidney. A comprehensive expression proﬁle of the members of
the IGF system in human kidney is depicted in this ﬁgure. However this ﬁgure does not represent a complete proﬁle.
CCD, cortical collecting duct; DT, distal tubule; G, glomerulus; MCT, medullary collecting duct; PT, proximal tubule.
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The IGF system is expressed in a complicated manner
within the kidney and has profound effects on kidney
growth, structure, and function [50–53]. However, less
information is available about the expression of the IGF
system in human kidney. A composite of the location
of IGFs, their receptors, and high- and low-afﬁnity IGF
binding proteins in the human kidney is provided in Fig. 2.
IGF-II is synthesized by the glomerular and peritubular
vasculature as well as the interstitium, whereas IGF-I is
expressed to a lesser extent in the glomerular vasculature
[54–56]. Both IGF-I and -II receptors are present in all
locations of the human kidney. This IGF-IGFR expression
pattern suggests a possible autocrine/paracrine action of
IGFs, in particular IGF-II in the glomerulus in addition to
their endocrine actions. The IGFBPs and IGFBP-rPs are
expressed in various segments of the kidney. IGFBP-1, -2,
-4, and -5 and IGFBP-rP1, -rP2, and -rP4 are produced in
the glomerulus predominantly. On the other hand, expres-
sion of IGFBP-3 and -6, and IGFBP-rP3 shows cortical
predominance [54,56,57]. Although the current picture of
the expression proﬁle of the IGF system in the human
kidney is incomplete, heterogeneous expression of IGFBPs
and IGFBP-rPs with varying abundance implies site-spe-
ciﬁc IGF-dependent and/or IGF-independent actions of
IGFBPs and IGFBP-rPs in the human kidney.Physiologic signiﬁcance of the endocrine-derived IGFs
and IGFBPs has been extensively studied in animals, in
particular using transgenic (TG) mice. Administration of
IGF-I to animals promotes renal growth through a process
of cellular hypertrophy and hyperplasia, and induces a
rapid increase in renal blood ﬂow and glomerular ﬁltration
together with a reduction in renal vascular resistance [58].
In addition, overexpression of IGF-I in TG mice induces
renal and glomerular hypertrophy [59–61]. However, no
renal developmental abnormalities have been reported in
newborn IGF-I knockout (KO) mice [62,63]. Although 95% of
IGF-I KO mice die immediately after birth, the mice that
survive are smaller than their wild-type littermates and the
weight of their kidneys is proportionally lower, along with
reduced glomerular size and number of nephrons, suggest-
ing that IGF-I plays a critical role in number of nephrons
and enhances function in developing kidneys [64]. Kidney
weight is decreased in two hepatic IGF-I deﬁciency models,
probably as a result of the decreased serum IGF-I levels,
because systemic delivery of IGF-I has been shown to
increase kidney size [65,66]. On the other hand, kidney
weight is increased in IGF-II TG mice [67,68]. IGFBP-1 TG
mice display a small reduction in kidney weight, although
proportional to body weight [69,70], and develop glomer-
ulosclerosis without glomerular hypertrophy [71]. Infusion
of IGFBP-1 into GH-deﬁcient dwarf mice stimulates renal
but not body growth [72]. However, excessive levels of
IGFBP-1 appear to have an adverse effect on the kidney, as
Kidney Res Clin Pract 31 (2012) 26–3730IGFBP-1 TG mice have a reduced number of nephrons and
develop glomerulosclerosis [73,74]. IGFBP-2 overexpression
inhibits GH-stimulated body and kidney growth in GH TG
mice [75]. Kidney growth is disproportionately retarded by
IGFBP-3 overexpression, most likely by inhibiting IGF
action [76]. These data clearly demonstrate IGF-dependent
inhibitory effect of IGFBPs in vivo.
It is also evident that in addition to GH and IGFs in
circulation, locally produced IGFs, high-afﬁnity IGFBPs and
low-afﬁnity IGFBP-rPs may also affect the kidney. Infusion
of IGF-I directly into the renal parenchyma results in
hypertrophy and hyperplasia of the medullary thick
ascending limb (mTAL) and distal tubule whereas proximal
tubules are not affected [77], along with minimal IGF-IR
gene expression in proximal tubules [78]. IGF-I produced
in the mTAL may play a trophic role in conditions asso-
ciated with increased workload, such as unilateral
nephrectomy and high-protein diet. In vitro, IGF-I is a
potent mitogen for cultured glomerular mesangial cells
and stimulates the production of ECM by mesangial cells
[79–81]. IGFBP-3 alone inhibits tubular cell DNA synthesis
and induces apoptosis in an IGF-dependent and -indepen-
dent manner [82,83]. This IGF-independent induction of
apoptosis appears to be in part through increase of
oxidative stress in porcine proximal tubular epithelial
cells [84]. IGFBP-3 also mediates tumor necrosis factor-a
(TNF-a)-induced mesangial cell apoptosis [85]. Further-
more, IGFBP-3 plays an important role in the development
of podocyte apoptosis by modulation of transforming
growth factor-b (TGF-b) and bone morphogenetic pro-
tein-7 (BMP-7)-induced proapoptotic- and antiapoptotic
signals [86]. IGFBP-5 also exhibits IGF-independent
actions. IGFBP-5 is able to mediate mesangial cell migra-
tion through activation of cdc42, and laminin421 binding
to a6b1-integrin [87]. With respect to low-afﬁnity IGFBP-rPs,
IGFBP-rP2/connective tissue growth factor (CTGF) induces
renal ﬁbrosis in a TGF-b-dependent and -independent
manner [88,89].
Limited information is available regarding physiologic
signiﬁcance of the IGF system in the human kidney. IGF-I
increases renal blood ﬂow and growth factor receptor
(GFR) and causes sodium retention and volume expansion
[90]. Sodium retention occurs as a consequence of a direct
effect on renal tubules, due to stimulation of renin release
and suppression of atrial natriuretic peptide secretion
[91]. IGFBP-rP2/CTGF, a potent regulator of cell prolifera-
tion, migration, and matrix production, is expressed in the
immediate precursors of glomerular visceral and parietal
epithelial cells in the comma- and S-shaped stages, but not
in earlier stages of nephron development [92]. It is also
present on precursors of mesangium and glomerular
endothelium, suggesting a possible role in normal glomer-
ulogenesis and maintenance of glomerular structure and
function at adult age. In addition, IGFBP-rP2/CTGF pro-
motes the transdifferentiation of human renal tubular
epithelial cells toward myoﬁbroblasts in vitro, suggesting
a critical role of IGFBP-rP2/CTGF in interstitial ﬁbrosis
[93,94].The IGF system in CKD
Ample studies indicate that CKD is associated with
several derangements in the GH–IGF–IGFBP axis. Pertur-
bations in this somatotropic hormone axis are responsible
for many important complications seen in CKD, such as
growth retardation and catabolism, as well as disease
progression. Circulating levels of GH are a balance
between the production rate and metabolic clearance.
GH synthesis may be reduced, normal, or even increased
in CKD [95]. GH secretion is normal or low in late
prepubertal and pubertal children with chronic renal fail-
ure (CRF) [96]; whereas GH secretion rates are increased
with increased GH burst frequency in prepubertal children
and in adults with ESRD [96–98]. The release of GH in
response to GH-releasing hormone is increased in adults
[99], whereas in children, the mid- to-late adolescent
increase in GH production fails to occur in CKD [96]. The
metabolic clearance rate of GH is obviously decreased in
advanced CKD [100]. Overall, plasma GH levels are normal
or increased in patients with CKD. Growth retardation is a
signiﬁcant complication in children with CKD and occurs
even though serum GH levels are normal or even elevated,
reﬂecting a state of acquired GH resistance.
With respect to circulating IGF-I, it has been demon-
strated that serum IGF-I levels are normal or low in
children with advanced CKD [101], whereas, in adult
patients, serum IGF-I levels are reduced only in patients
with cachexia [102]. The rate of IGF-I production is
reduced in children with uremia [103], but appears to be
normal in adults with ESRD [104,105]. Insensitivity to IGF-
I is an important cause of GH resistance, and this appears
to arise because of the accumulation of circulating IGFBPs
that are normally cleared through the kidney. Serum
levels of IGFBP-1, -2, -4, and -6 are elevated. With serum
IGFBP-3, immunoreactive IGFBP-3 levels are elevated
because of an increase of immunoreactive IGFBP-3 frag-
ments, which have reduced IGF-I afﬁnity, whereas intact
IGFBP-3 levels are not elevated [106–109]. Therefore, the
bioavailability of IGF-I in CKD is compromised because of
increased levels of IGFBP-1, -2, -4, and -6 [110–112].
Furthermore, as a result of increased proteolysis of
IGFBP-3, less IGF-I circulates as the 150-kDa ternary
complex normally comprising IGF-I, intact IGFBP-3, and
ALS. Consequently, effective delivery of IGF-I to its sites of
action is reduced. Thus, IGF bioavailability is signiﬁcantly
reduced in CKD due to increased production and reduced
clearance of IGFBPs with impaired kidney function, which
results in decreased IGF bioactivity of CKD serum despite
normal total IGF levels. It is also conceivable that tissue
IGF-I resistance may arise due to altered local IGFBP
production and accumulation. It has been suggested that
administration of an inactive IGF-I analog might be used
to displace IGF-I from IGFBPs in CKD and thus restore IGF-I
bioactivity [113]. It is of note that the functional IGF
deﬁciency in nephrotic syndrome (NS) appears to result
from low levels of serum IGFBPs as well as serum IGFs due
to increased urinary losses of serum IGF–IGFBP complexes
[114]. Some studies show that in children with NS, serum
IGFBP-3 returned to normal levels and IGF-I was still
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cate that both IGF-I and IGFBP-3 returned to normal levels
[115]. It is evident that serum IGF-I and IGFBPs are altered
with different stages of CKD, the speed of onset, the
amount of proteinuria, and the potential of remission.
It is known that patients with diabetes and microalbu-
minuria also present with severe alterations in the GH–
IGF–IGFBP system, with increased IGF-I renal levels and
IGFBP-3 protease activity, increased excretion of bioactive
GH, IGF-I, and IGFBP-3, but decreased circulating intact
IGFBP-3 levels [116]. Patients with type 1 diabetes have an
increased level of circulating GH and less high-afﬁnity GH-
binding protein, the soluble ectodomain of the GH recep-
tor, which indirectly indicates a decrease in the number of
GH receptors in these patients [117]. This leads to a state
of GH resistance, and thus a decrease in the levels of IGF-I
and IGFBP-3 [118–120]. In contrast, IGFBP-1 levels are
signiﬁcantly higher in patients with diabetes and micro-
albuminuria than in healthy adolescents [121,122]. IGFBP-
1 serum concentration is inversely related to insulin levels
[122]; therefore, the relative portal insulinopenia in
patients with diabetes is associated with increased
IGFBP-1 levels and consequent reduction of IGF-I bioavail-
ability [123]. In children and adolescents with diabetes
there is an association between urinary IGF-I and kidney
volume as well as microalbuminuria, suggesting a role of
IGF-I in the pathogenesis of diabetic nephropathy (DN)
[124]. A longitudinal assessment of IGF-I levels in young
patients with childhood onset type 1diabetes shows that
patients developing microalbuminuria have lower total
and free IGF-I levels than control patients [125]. Adoles-
cents with diabetes and microalbuminuria have lower
IGFBP-3 serum concentrations, but higher levels of urinary
IGFBP-3 than control patients [121,122]. This increased
urinary IGFBP-3 is related to incipient nephropathy, and
not simply to poor metabolic control. Indeed, adolescents
with diabetes and microalbuminuria show higher levels of
urinary IGFBP-3 present as both intact form and frag-
ments, and even when compared with patients without
microalbuminuria, was matched for metabolic control
[126–128]. Because IGFBP-3 has the ability to induceTable 1. GH–IGF–IGFBP Axis Proﬁle in Serum and Urine of Patients
with CKD and DN
GH–IGF–IGFBP
Serum levels Urine levels
CKD DN CKD DN
GH ¼ ,m ¼ ,k k,(min NS) m
IGF-I ¼ ,k k k,(min NS) m
IGF-II ND ND ND ND
IGFBP-1 m m k,(m in NS) m
IGFBP-2 m ND k,(m in NS) m
IGFBP-3 k k k,(m in NS) m
IGFBP-4 ¼ k k,(m in NS) m
IGFBP-5 ¼ k k,(m in NS) m
IGFBP-6 m ND k,(m in NS) m
CKD, chronic kidney disease; DN, diabetic nephropathy; equal sign, no
change; GH, growth hormone; IGF, insulin-like growth factor; IFGBP,
insulin-like growth factor binding protein; ND, no data in available
literature; NS, nephritic syndrome.mesangial apoptosis in the context of high ambient
glucose or TNF-a in the kidney [129], it has been sug-
gested that DN is associated with IGFBP-3 proteolysis in
urine, and the derived IGFBP-3 fragments may retain
biologic activity and contribute to increased albumin
excretion through increased apoptosis of glomerular
epithelial and endothelial cells [128]. Table 1 summarizes
the published data on the GH–IGF–IGFBP proﬁles in
patients with CDK and DN.
It has also been reported that IGFBP-rP-2/CTGF, a direct
mediator of TGF-b-induced ﬁbrosis, show a signiﬁcant
increase of serum levels in patients with DN and corre-
lated with albuminuria, creatinine clearance, duration of
diabetes, and glycemic control [130]. In addition, in
patients with diabetes and microalbuminuria or DN,
urinary IGFBP-rP2/CTGF levels are increased [131,132]
and signiﬁcantly correlated with urinary albumin excre-
tion, and glomerular ﬁltration rate [130]. A recent pro-
spective study, with a 12.8-year follow-up period,
performed in 198 adult patients with type 1 diabetes,
has shown that plasma IGFBP-rP2/CTGF is an independent
predictor of ESRD and mortality in patients with DN [133].
In a manner similar to TGF-b, IGFBP-rP2/CTGF present in
the renal tubular ﬂuid may act directly on tubular epithe-
lial cells and induce the expression of ECM proteins,
thereby causing tubulointerstitial ﬁbrosis [134].
Patients with active glomerulosclerosis (FSGS) excrete
high amounts of podocalyxin- positive cells as well as
IGFBP-1 and -3 [135]. Furthermore, IGFBP-1 and -3 are
upregulated in response to TGF-b and bradykinin in
human podocytes and microvascular endothelial cells.
These ﬁndings suggest that the local expression of IGFBPs,
in particular IGFBP-1 and IGFBP-3 in podocytes and
endothelial cells, might contribute to the pathogenesis of
glomerular disease. In addition, IGFBP-rP2/CTGF appears
to be abundant in FSGS and is associated with develop-
ment of severe FSGS, glomerulonephritis, glomerulo-
sclerosis, hypertensive nephrosclerosis, and kidney
allograft ﬁbrosis [92,136–138].Therapeutic use of the IGF system in CKD
Prevention and treatment of CKD has been based on
early and aggressive treatment of hypertension. Distur-
bances of the GH–IGF–IGFBP axis in CKD have suggested
therapeutic roles for both inhibition, as well as stimula-
tion, of that axis in CKD. Experimental data suggest that
antagonists of the GH/IGF-I system, including somatosta-
tin analogs, GHR and IGF-IR antagonists as well as antago-
nists of downstream factors activated by GH/IGF-I, such as
the angiotensin-converting enzyme and AGE systems, may
have beneﬁcial effects on the diabetic kidney in animal
models [139–141]. A novel somatostatin analog PTR-3173,
which exerts a prolonged inhibitory action selectively on
the GH-IGF axis, but not on insulin secretion, shows
blunted renal/glomerular hypertrophy, albuminuria, and
glomerular ﬁltration rate in the nonobese diabetic (NOD)
mice, presumably through prevention of renal IGF-I accu-
mulation [139]. Furthermore, a speciﬁc GH receptor
Kidney Res Clin Pract 31 (2012) 26–3732antagonist (GHRA), G120K-PEG, exhibits normalization of
the diabetes-associated renal hypertrophy and glomerular
enlargement in mice with diabetes [121,141]. Most impor-
tantly, this GHRA lowers the diabetes-induced rise in
urinary albumin excretion. In addition, late intervention
with GHRAs, alone or in combination with angiotensin-
converting enzyme inhibitors in NOD mice with manifest
renal changes, shows regression in some diabetes-asso-
ciated renal changes (e.g., urinary albumin excretion and
renal hypertrophy) [141]. These promising preclinical
data strongly suggest that GHR blockade is a viable,
new modality for treating or preventing diabetic renal
complications.
On the other hand, the administration of IGF-1 has been
reported in a number of small studies to show some
beneﬁcial effects on CKD and ESRD. IGF-I improves renal
function after acute renal failure [142] and in CRF
[143,144]. IGF-I administration results in an improvement
in renal function and an increase in kidney size over 4 days
in patients with advanced CRF [145]. In a second, pro-
longed study with ESRD, using the same dose of IGF-I, it
results in a modest increase of GFR after 4 days. However,
some patients treated with IGF-I for 13 and 27 days
showed no long-term effect on insulin clearance or
p-aminohippurate clearance, which might be attributed to
administration of the large dose of IGF-I [146]. Further
studies indicate that administration of a half amount of
IGF-I (50 mg/kg/day) intermittently (4 days on treatment,
3 days off treatment) can improve renal function to that
achieved by dialysis [133]. These studies support a poten-
tial role of IGF-I in CKD to delay the need for dialysis.
Because CKD presents a state of IGF-I resistance due to
elevated serum IGFBPs, it has been suggested that admin-
istration of an inactive IGF-I analog such as Leu24,59,60Ala31–
IGF-I and Leu24Ala31–IGF-I, which retain afﬁnity for binding
to the IGFBPs but show no activity on the IGF receptor,
might be used to displace IGF-I from IGFBPs in CKD and
thus restore IGF-I bioactivity [147,148]. Indeed, these IGF
displacers produce IGF-I-like effects including increased
kidney size and markers of kidney function as well as
stimulated whole body weight gain and bone growth in
two animal models of IGF-deﬁciency [113,148]. In addition,
IGFBP-1 could be an attractive speciﬁc target for displace-
ment in CRF, because there is evidence that IGFBP-1 may
have an important role in inhibiting serum IGF-I bioavail-
ability [149]. Particularly when phosphorylated, IGFBP-1
has a higher afﬁnity for IGFs than membrane-bound IGF
receptors and the high levels of IGFBP-1 in CRF are
negatively correlated with both linear growth and GFR.
Furthermore, IGFBP-1 levels normalize after a successful
renal transplantation [149]. In this respect, novel peptides
that show remarkable speciﬁcity for IGFBP-1 have been
discovered [148], and further studies would warrant their
application as novel therapeutics in CRF.
DN, one of the major microvascular complications of
diabetes, is characterized by excessive collection of ECM
with thickening of glomerular and tubular basement
membranes and increased amount of mesangial matrix,
which ultimately progresses to glomerulosclerosis and
tubulointerstitial ﬁbrosis. It has been identiﬁed that oneof the common characteristics of glomerulosclerosis, tubu-
lointerstitial ﬁbrosis, and arterial media hypertrophy
lesions of hypertensive nephrosclerosis, is a signiﬁcant
increase of IGFBP-rP2/CTGF tissue expression, which is
associated with a concomitant increase in IGFBP-rP2/CTGF
in serum and urine [136]. Recent studies further demon-
strate that suppression IGFBP-rP2/CTGF results in success-
ful inhibition of proteinuria and subsequent suppression
of genes involved in mesangial matrix expansion in mouse
models of type 1 diabetes, providing further support for a
pathogenetic role of IGFBP-rP2/CTGF in DN [150]. These
ﬁndings identify IGFBP-rP2/CTGF as a promising interven-
tion for renal ﬁbrosis. Indeed, FG-3019, a fully human
monoclonal neutralizing immunoglobulin G antibody
against IGFBP-rP2/CTGF, has been developed by FibroGen
(San Francisco, CA, USA) for the treatment of ﬁbrotic
diseases and diabetic complications. Recent clinical phase
1 studies demonstrate the safety and efﬁcacy of this
antibody in patients with diabetes and microalbuminuria
[151]. It is conceivable that IGFBP-rP2/CTGF would
become an effective and safe therapeutic option for the
treatment of progressive renal ﬁbrosis in the near future.Conclusion
During the past decade there has been a steady pro-
gress in our understanding of the role of the GH–IGF–
IGFBP axis in the maintenance of normal renal function
and the pathogenesis and progression of CKD. Ample
evidence also indicates that GH and IGF-I are involved in
the pathogenesis of DN and growth failure in children
with CKD. It appears that not only GH and IGFs in
circulation, but also locally produced IGFs, high-afﬁnity
IGFBPs, and low-afﬁnity IGFBP-rPs alter with different
stages of CKD, thereby resulting in dysregulation of the
endocrine, paracrine, and autocrine effects of the GH–IGF–
IGFBP axis. However, information regarding the impact of
the GH–IGF–IGFBP axis in different stages of CKD and its
corresponding complications is limited. A holistic under-
standing of the GH–IGF–IGFBP axis in the multifaceted
nature of CKD could provide an opportunity to develop
new therapeutic strategies to improve the management of
the patient with this devastating disease.Conﬂict of interest
The author has nothing to declare.
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